Search Results
12 items found for "Sudarshan Rajagopal"
- Naggie and Rajagopal Elected Members of American Society for Clinical Investigation
March 2022 "March 3, 2022 Susanna Naggie, MD, and Sudarshan Rajagopal, MD, PhD Two School of Medicine faculty members — Susanna Naggie, MD , and Sudarshan Rajagopal, MD, PhD — have been elected to the Naggie and Rajagopal are two of 95 new members elected to the society for 2022.
- 📰 GPCR Weekly News, February 12 to 18, 2024
Sudarshan Rajagopal, et al. for their finding that GPCR kinases affect biased signaling downstream of Franziska Heydenreich, Sudarshan Rajagopal, Graham Ladds, and Michel Bouvier.
- 📰 GPCR Weekly News, April 17 to 23, 2023
Bryan Roth, Sudarshan Rajagopal, and Graeme Milligan. Save the date! Dr.
- 📰 GPCR Weekly News, March 4 to 10, 2024
Franziska Heydenreich, Sudarshan Rajagopal, Graham Ladds, Cesare Orlandi, Simone Prömel and Michel Bouvier
- 📰 GPCR Weekly News, August 21 to 27, 2023
Sudarshan Rajagopal and their lab team study on 'Location bias: A "Hidden Variable" in GPCR pharmacology
- 📰 GPCR Weekly News, February 26 to March 3, 2024
Franziska Heydenreich, Sudarshan Rajagopal, Graham Ladds, Cesare Orlandi, Simone Prömel and Michel Bouvier
- 📰 GPCR Weekly News, February 5 to 11, 2024
Franziska Heydenreich, Sudarshan Rajagopal, Graham Ladds, Cesare Orlandi and Michel Bouvier.
- 📰 GPCR Weekly News, January 22 to 28, 2024
Franziska Heydenreich, Sudarshan Rajagopal, Graham Ladds, and Michel Bouvier We will also have a poster
- 📰 GPCR Weekly News, June 17 to 23, 2024
activation-based BRET sensors differentially report on GPCR-G protein coupling Samuel Liu, Preston Anderson, Sudarshan Rajagopal, Robert Lefkowitz, Howard Rockman for their review G Protein-Coupled Receptors: A Century
- 📰 GPCR Weekly News, February 19 to 25, 2024
Franziska Heydenreich, Sudarshan Rajagopal, Graham Ladds, Cesare Orlandi, Simone Prömel and Michel Bouvier
- 📰 GPCR Weekly News, January 29 to February 4, 2024
Franziska Heydenreich, Sudarshan Rajagopal, Graham Ladds, and Michel Bouvier.
- Chemokine receptor-targeted drug discovery: progress and challenges
receptor with a certain effector, thus enriching a specific signaling pathway (Smith, Lefkowitz, and Rajagopal